Standard Biotools Inc revenue growth has been varied year-over-year.

What is LAB's revenue growth rate?

Historical revenue data is available for Standard Biotools Inc to analyze growth trends.

How fast is LAB earnings growing?

Earnings growth data is available for Standard Biotools Inc analysis.

What is LAB's profit margin?

Standard Biotools Inc currently has a net profit margin of 90.7%.

LAB Revenue & Earnings Growth Analysis 2026 - Is Standard Biotools Inc Growing?

Growth Summary

Standard Biotools Inc (LAB) has experienced challenges in growth. The company operates in the Healthcare sector, specifically in the Medical Devices industry.

Over the past 4 years, Standard Biotools Inc has achieved a revenue compound annual growth rate (CAGR) of 40.6%, while earnings have grown at 27.2% CAGR.

The company's net profit margin stands at 90.7%, indicating strong profitability.

Latest Revenue

$174.43M

Net Income

$-138885000.00

5-Year Revenue CAGR

40.6%

4 years of data

Net Margin

90.7%

Latest period

Revenue Growth Over Time

Historical revenue and profitability trends for Standard Biotools Inc

The chart above illustrates Standard Biotools Inc's revenue trajectory over the past 4 years. The revenue pattern shows the challenges the company has faced in recent periods.

Year-over-Year Growth Rates

Annual percentage change in revenue and earnings

Growth rates provide insight into the momentum of Standard Biotools Inc's business.

Profit Margin Trends

How efficiently Standard Biotools Inc converts revenue into profit

Understanding Profit Margins

Profit margins reveal how much of each dollar of revenue Standard Biotools Inc retains at different stages:

Gross Margin (N/A%): What remains after direct production costs
Operating Margin (N/A%): Profit from core operations before interest and taxes
Net Margin (90.7%): Final profit after all expenses

A net margin above 15% indicates Standard Biotools Inc is highly profitable relative to its revenue base.

Future Growth Outlook

Analyst estimates and forward-looking indicators

EPS Estimate 2026

$0.03

Current: $-0.52

EPS Estimate 2027

$-0.01

-133.3% expected growth

Price Target

$1.55

Analyst consensus

What Analysts Are Saying

Wall Street analysts project Standard Biotools Inc to continue focusing on sustainable operations. The consensus analyst rating is 4.3333 based on 3 analysts.

Growth Analysis Conclusion

Based on our comprehensive analysis, Standard Biotools Inc (LAB) demonstrates declining growth characteristics.

Key Takeaways:

Revenue Growth:, 40.6% CAGR over 4 years
Profitability: Net margin of 90.7% shows the company is investing in growth over short-term profits
Efficiency:

Investment Considerations

This growth analysis provides a comprehensive view of Standard Biotools Inc's historical performance and future outlook. Investors should consider these growth metrics alongside valuation, competitive positioning, and broader market conditions when making investment decisions. Past performance does not guarantee future results.